Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Valneva, DoD Ink $59M IXIARO Supply Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News

Valneva, DoD Ink $59M IXIARO Supply Pact

Valneva will supply IXIARO in a contract potentially worth as much as $70 million

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Valneva SE, a biotech company developing and commercializing vaccines for infectious diseases, has signed a new $59 million contract with the U.S. government Department of Defense for the supply of its Japanese encephalitis (JE) vaccine Ixiaro.  

Valneva will supply Ixiaro doses to the Defense Logistics Agency of the U.S. Department of Defense, through 2019 and the beginning of 2020 with a value of $59 million guaranteed and potentially worth up to $70 million. A delivery schedule is being prepared and supply shipments will commence immediately. 

Franck Grimaud, chief business officer of Valneva said, “We are pleased to continue our important collaboration with the U.S. government to fight this deadly disease. The U.S. military has been using Ixiaro since 2010 and we are excited to further support the expansion of its use and help protect military personnel and their families from Japanese encephalitis.”  

Ixiaro is the only JE vaccine approved by the U.S. FDA. It was developed through a cooperative research and development agreement with the Walter Reed Army Institute of Research. Valneva markets and distributes Ixiaro directly to the U.S. military and U.S. private market. In October the FDA approved an accelerated Ixiaro vaccination schedule of two doses administered seven days apart, compared to the previous 28 day schedule.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters